Systems and methods are disclosed herein for switching control of an ambulatory medical device from an application executing on the ambulatory medical device to a safe version or a new version of the application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device can maintain copies of a safe version and a new version of the application. The disclosed systems and methods can execute the new version, while the prior version of the application continues to execute, determine whether a minimum set of operating conditions are satisfied by the new version, and switch control of the ambulatory medical device from the prior version to the new version. The systems and methods can also automatically revert to the safe version of the application case the current version is malfunctioning without interrupting therapy provided to the subject.

Described are means for the direct and continuous connection of a catheter to the lumen of any tubular anatomical structure, or ductus, without medically significant leakage. A port implanted at the body surface with piping to a periductal collar allows drug or radionuclide delivery that bypasses the upstream lumen. The port allows injection, infusion, aspiration, or attachment of an automatic ambulatory pump. A superparamagnetic nanoparticle carrier-bound drug, for example, can be introduced into the lumen to pass downstream until the particles, with or without the drug still bound, are drawn into the lumen wall by a magnetized jacket surrounding the ductus. Such constitutes a method of drug targeting whereby a segment of a vessel or the territory supplied by a branch of that segment can be circumscribed for exposure to the drug. A jacket with side-entry connector positioned in surrounding relation to a lesion requiring treatment can itself be magnetized.

Embodiments relate to subcutaneous insertion systems comprising a surface device to be applied to a patient's skin and an insertion system for applying the surface device to the patient, wherein the applying can include subcutaneous insertion of a cannula or other element, and related devices and methods. The surface device comprises a surface for application to the skin of a patient and a subcutaneous element, such as a cannula, wire, filament or other device, extending from the skin's surface at an angle greater than 0 degrees and less than 90 degrees.

Provided herein are systems and methods for monitoring one or more health or physiological parameters in a subject. The systems and methods may comprise a patch coupled to an injector. Data may be transmitted to a mobile device or remote server, where the data may be processed. Processed data may be used to inform a subject on a health or physiological condition.

An integrated system for injection including an injection device in electronic connection with a communication device is provided. The external communication device may be a handheld electronic device such as a Smartphone or a dedicated reader such as a reader capable of reading information contained on an RFID tag. The injection device includes a needle and a drug delivery portion enclosed within an external housing. Optionally, a plurality of sensors is affixed to the surface of the needle to collect data about the injection and physical characteristics of the patient. The data may be recorded on a data capture module. The electronic chip may be a readable and writable electronic chip such as a non-volatile memory chip. Alternatively, the electronic chip is a passive RFID tag. The injection device may further include a data transmitter for sending information obtained from the data capture module to the external communications device.

An apparatus for insertion of a medical device in the skin of a subject is provided.

An apparatus for insertion of a medical device in the skin of a subject is provided.

A diagnostic Electrochemical Impedance Spectroscopy (EIS) procedure is applied to measure values of impedance-related parameters for one or more sensing electrodes. The parameters may include real impedance, imaginary impedance, impedance magnitude, and/or phase angle. The measured values of the impedance-related parameters are then used in performing sensor diagnostics, calculating a highly-reliable fused sensor glucose value based on signals from a plurality of redundant sensing electrodes, calibrating sensors, detecting interferents within close proximity of one or more sensing electrodes, and testing surface area characteristics of electroplated electrodes. Advantageously, impedance-related parameters can be defined that are substantially glucose-independent over specific ranges of frequencies. An Application Specific Integrated Circuit (ASIC) enables implementation of the EIS-based diagnostics, fusion algorithms, and other processes based on measurement of EIS-based parameters.

A blood sugar regulation system including: a blood sugar sensor; an insulin injection device; and a processing and control unit predicting the future evolution of the blood sugar based on a physiological model and accordingly controlling the insulin injection device, wherein the processing and control unit is capable of: a) implementing a calibration of the model by taking into account a history of the measured blood sugar; b) at the end of the calibration step, determining whether the model is satisfactory or not based on at least one numerical indicator representative of the error between the blood sugar estimated based on the model and the real blood sugar measured by the sensor; and c) if the quality of the model is not satisfactory, controlling the insulin injection device without taking into account the predictions made from the model.

Disclosed herein are techniques for closed-loop control based on predicted trajectories. The techniques may involve predicting a trajectory of a glucose level of a patient based on past observations of the glucose level. The techniques may further involve determining a cost expression based on the predicted trajectory. The cost expression may be based on a duration of time that the trajectory is predicted to extend outside of a target glucose concentration range. Additionally, the techniques may involve affecting, based on the cost expression, at least one future command to at least one infusion pump so as to shorten the duration of time that the trajectory is predicted to extend outside of the target glucose concentration range.